Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Adial Pharmaceuticals, Inc.

NASDAQ: AZR · Life Sciences · 8 alerts · CIK 1513525

Share price
$3.81Close, Nov 16
Market cap
$54.4M
Shares outstanding
14.29MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Adial Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:08 PM ET 8-K
Financial Results

Azora Therapeutics Financial Results

Azora Therapeutics reported its third quarter 2026 financial results, highlighting its recent transition to the Nasdaq under the ticker 'AZR' and the appointment of a new executive leadership team. The company remains on track to submit an IND and initiate a Phase 1a trial for its lead candidate AT177 in the first half of 2027.

“With our transition to Nasdaq, Azora is well positioned for success to bring AhR biology to people living with ulcerative colitis. We are pleased to have recently strengthened our leadership team, appointing Celia Economides as CFO and David Rubenstein, M.D., Ph.D., as Chief Scientist. Dr. Rubenstein led the development and FDA approval of the first AhR agonist. We have further added to our depth of experience through the appointment of new Board members who bring inflammatory disease, clinical development and company building expertise to Azora. Our focus now is execution excellence, and we remain on track to submit an IND for AT177 and initiate our Phase 1a trial in the first half of 2027.”

Matt Davidson, Ph.D., President, Co-Founder and Chief Executive Officer
4:07 PM ET 10-Q
Financial Results

Azora Therapeutics Q3 2026 Results: Net Loss of $64.6M, Loss Widens

Azora Therapeutics, Inc. (formerly Adial Pharmaceuticals) reported a significant net loss of $118.6 million for the nine months ended September 30, 2026, primarily driven by a $46.2 million charge for acquired in-process R&D and a $48.8 million change in the fair value of milestone warrant rights. Following its acquisition of Legacy Azora in June 2026, the company's cash position increased to $22.0 million, supported by $26.8 million in proceeds from a private placement of pre-funded warrants.

Key figure
Net loss $64.6M
7:30 AM ET 8-K
Leadership Change

Azora Therapeutics Leadership Change

Azora Therapeutics appointed Aida Habtezion, M.D., Paul Hastings, and Thomas Soloway to its Board of Directors. The appointments include the reconstitution of the board's audit, compensation, and nominating committees, with Mr. Soloway serving as audit committee chair. All three new directors were determined to be independent under Nasdaq listing standards.

4:31 PM ET 8-K
Leadership Change

Adial Pharmaceuticals Leadership Change

Adial Pharmaceuticals (renamed Azora Therapeutics) appointed Matthew Davidson, Ph.D. as President and CEO and Celia Economides as CFO, effective October 28, 2026. Dr. Davidson succeeds Cary J. Claiborne, whose employment was terminated. The leadership transition coincides with a corporate rebranding and a shift in focus toward advancing the company's ulcerative colitis candidate, AT177.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.